Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Solid Cancers

Busulfan–melphalan in high-risk neuroblastoma: the 30-year experience of a single institution

Bone Marrow Transplantation volume 51, pages 1076–1081 (2016)Cite this article

Subjects

Abstract

High-dose chemotherapy (HDC) was investigated in high-risk neuroblastoma (HR-NBL) to reduce the risk of relapse. We report the results of the 30-year experience of a cohort of patients with HR-NBL treated with high-dose (HD) busulfan (Bu)-containing regimens. From 1980 to 2009, 215 patients aged >1 year with stage 4 NBL were treated with HD Bu-containing regimens at Gustave Roussy. These data were prospectively recorded in the Pediatric Transplantation Database. The median age at diagnosis was 40 months (12–218 months). All patients had a stage 4 neuroblastoma. NMYC amplification was displayed in 24% of the tumors. The hematopoietic support consisted of bone marrow or PBSCs in 46% and 49% of patients, respectively. The 5-year event-free survival and overall survival rates of the whole cohort were 35.1% and 40%, respectively. Age at diagnosis, bone marrow involvement and tumor response after induction chemotherapy were significant prognostic factors. Toxicity was manageable and decreased over time, owing to both PBSC administration and better supportive care. Based on this experience, HD Bu–melphalan (Mel) has been implemented in Europe and compared with Carboplatin–Etoposide–Mel in the European SIOP Neuroblastoma (SIOPEN)/HR-NBL randomized protocol. It has now become the standard HDC in the SIOPEN HR strategy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 2009; 27: 1007–1013; Errata, J Clin Oncol 2014; 32: 1862–1863.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165–1173.

    Article  CAS  PubMed  Google Scholar 

  3. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6: 649–658.

    Article  CAS  PubMed  Google Scholar 

  4. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR et al. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomized trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005; 44: 348–357.

    Article  PubMed  Google Scholar 

  5. Vitale V, Franzone P . The role of TBI in conditioning regimens for children. Bone Marrow Transplant 1991; 7 (Suppl 3): 32–34.

    PubMed  Google Scholar 

  6. Frei E 3rd, Teicher BA, Holden SA, Cathcart KN, Wang YY. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48: 6417–6423.

    CAS  PubMed  Google Scholar 

  7. Ciurea SO, Andersson BS . Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 523–536.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Flandin I, Hartmann O, Michon J, Pinkerton R, Coze C, Stephan JL et al. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology. Int J Radiat Oncol Biol Phys 2006; 64: 1424–1431.

    Article  PubMed  Google Scholar 

  9. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993; 11: 1466–1477.

    Article  CAS  PubMed  Google Scholar 

  10. Frappaz D, Michon J, Hartmann O, Bouffet E, Lejars O, Rubie H et al. Etoposide and carboplatin in neuroblastoma: a French Society of Pediatric Oncology phase II study. J Clin Oncol 1992; 10: 1592–1601.

    Article  CAS  PubMed  Google Scholar 

  11. Coze C, Hartmann O, Michon J, Frappaz D, Dusol F, Rubie H et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol 1997; 15: 3433–3440.

    Article  CAS  PubMed  Google Scholar 

  12. Valteau-Couanet D, Michon J, Boneu A, Rodary C, Perel Y, Bergeron C et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005; 23: 532–540.

    Article  CAS  PubMed  Google Scholar 

  13. Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G et al. Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol 2010; 28: 3516–3524.

    Article  CAS  PubMed  Google Scholar 

  14. Bostrom B, Enockson K, Johnson A, Bruns A, Blazar B . Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant 2003; 7: 12–28.

    Article  PubMed  Google Scholar 

  15. Vassal G, Michel G, Espérou H, Gentet JC, Valteau-Couanet D, Doz F et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008; 61: 113–123.

    Article  CAS  PubMed  Google Scholar 

  16. Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D et al. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer 2012; 48: 3063–3072.

    Article  CAS  PubMed  Google Scholar 

  17. Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003; 32: 979–986.

    Article  CAS  PubMed  Google Scholar 

  18. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347–1353.

    Article  CAS  PubMed  Google Scholar 

  19. Beaujean F, Hartmann O, Pico J, Parmentier C, Hayat M, Lemerle J et al. Incubation of autologous bone marrow graft with ASTA Z 7557: comparative studies of hematological reconstitution after purged or nonpurged bone marrow transplantation. Pediatr Hematol Oncol 1987; 4: 105–115.

    Article  CAS  PubMed  Google Scholar 

  20. Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203–6207.

    CAS  PubMed  Google Scholar 

  21. Guerrini-Rousseau L, Goma G, Dufour C, Valteau-Couanet D. Varicella-zoster virus infections after high-dose chemotherapy and autologous stem cell transplantation in children with malignancies. EBMT Meet Abstr Book 2012; S143(P514).

  22. Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083–2088.

    CAS  PubMed  Google Scholar 

  23. Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 2012; 379: 1301–1309.

    Article  CAS  PubMed  Google Scholar 

  24. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562–1568.

    Article  CAS  PubMed  Google Scholar 

  25. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  PubMed  Google Scholar 

  26. Ladenstein RL, Poetschger U, Luksch R, Brock P, Castel V, Yaniv I et al. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: results from the HR-NBL1/SIOPEN trial. JCO - ASCO Annu Meet Abstr Part 2 2011; 29 (Suppl 18): 2.

    Article  Google Scholar 

  27. Hartmann O, Valteau-Couanet D, Vassal G, Lapierre V, Brugières L, Delgado R et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789–795.

    Article  CAS  PubMed  Google Scholar 

  28. Breslow N, McCann B . Statistical estimation of prognosis for children with neuroblastoma. Cancer Res 1971; 31: 2098–2103.

    CAS  PubMed  Google Scholar 

  29. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005; 23: 6474–6480.

    Article  CAS  PubMed  Google Scholar 

  30. George R, London WB, Maris JM, Cohn SL, Diller L, Look AT et al. Age as a continuous variable in predicting outcome for neuroblastoma patients with metastatic disease: impact of tumor biologic features. Proc Am Soc Clin Oncol 2003; 22: 799 (abstr 3213).

    Google Scholar 

  31. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23: 6459–6465.

    Article  CAS  PubMed  Google Scholar 

  32. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27: 298–303.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Ladenstein R, Poetschger U, Luksch R, Brock P, Castel V, Yaniv I et al. Influence of age and stage on outcome in the high risk neuroblastoma HR-NBL1/SIOPEN trial. Advanced Neuroblastoma Meeting (ANR) Abstract Book 2014, p246 (POC046).

  34. Valteau-Couanet D, Le Deley MC, Bergeron C, Ducassou S, Michon J, Rubie H et al. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high-dose chemotherapy. Pediatr Blood Cancer 2014; 61: 977–981.

    Article  CAS  PubMed  Google Scholar 

  35. Yanik G, Naranjo A, Parisi MT, Shulkin BL, Nadel H, Gelfand MJ et al. Impact of post-induction Curie scores as prognostic marker in high risk neuroblastoma. Biol Blood Marrow Transplant 2015; 21: S107.

    Article  Google Scholar 

  36. Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F et al. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol 2013; 31: 944–951.

    Article  CAS  PubMed  Google Scholar 

  37. Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer 2003; 98: 2488–2494.

    Article  CAS  PubMed  Google Scholar 

  38. Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600–607.

    Article  CAS  PubMed  Google Scholar 

  39. Haut PR, Cohn S, Morgan E, Hubbell M, Danner-Koptik K, Olszewski M et al. Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. Biol Blood Marrow Transplant 1998; 4: 38–42.

    Article  CAS  PubMed  Google Scholar 

  40. Valteau-Couanet D, Faucher C, Auperin A, Michon J, Milpied N, Boiron JM et al. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant 2005; 36: 547–552.

    Article  CAS  PubMed  Google Scholar 

  41. Valteau-Couanet D, Benhamou E, Vassal G, Stambouli F, Lapierre V, Couanet D et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937–942.

    Article  CAS  PubMed  Google Scholar 

  42. Brugieres L, Hartmann O, Benhamou E, Zafrani ES, Caillaud JM, Patte C et al. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome. Bone Marrow Transplant 1988; 3: 53–58.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Lorna Saint Ange for editing and Imène Hezam for the secretarial assistance.

Author information

Authors and Affiliations

  1. Department of Pediatric Oncology, Centre Hospitalier Universitaire, Angers, France

    S Proust-Houdemont

  2. Department of Pediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France

    C Pasqualini, C Dufour, M Semeraro, M-A Raquin, O Hartmann & D Valteau-Couanet

  3. Biostatistics and Epidemiology Unit, Gustave Roussy, Villejuif, France

    P Blanchard, E Benhamou & G Goma

Authors
  1. S Proust-Houdemont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Pasqualini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Blanchard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Dufour
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Benhamou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Goma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Semeraro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M-A Raquin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. O Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Valteau-Couanet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Valteau-Couanet.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Proust-Houdemont, S., Pasqualini, C., Blanchard, P. et al. Busulfan–melphalan in high-risk neuroblastoma: the 30-year experience of a single institution. Bone Marrow Transplant 51, 1076–1081 (2016). https://doi.org/10.1038/bmt.2016.75

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.75

Search

Advanced search

Quick links